Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China flag China · Delayed Price · Currency is CNY
6.44
+0.59 (10.09%)
Aug 20, 2026, 3:04 PM CST

Beijing SL Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-479.28-347.2-74.07416.69234.4425.94
Depreciation & Amortization
166.77166.77152.96145.4113.8899.8
Other Amortization
0.290.290.280.280.170.17
Loss (Gain) From Sale of Assets
0.050.05---0.21-3.22
Asset Writedown & Restructuring Costs
-338.17-338.17172.29-0.0100.02
Loss (Gain) From Sale of Investments
-2.34-2.34-13.13-239.47-98.13-209.01
Provision & Write-off of Bad Debts
---23.8131.9426.25
Other Operating Activities
246.51-0.23-0.661.05-5.99-4.38
Change in Accounts Receivable
-14.76-14.7662.4519.6682.88108.64
Change in Inventory
-436.26-436.26-102.33-4.250.58-11.5
Change in Accounts Payable
544.68544.6868.5166.5836.5617.54
Change in Other Net Operating Assets
621.15621.1511.09---
Operating Cash Flow
372.31257.66225.49460.2389.82464.63
Operating Cash Flow Growth
493.35%14.27%-51.00%18.05%-16.10%11.73%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-67.5-192.97-347.38-218.36-163.49-236.91
Sale of Property, Plant & Equipment
0000.011.477.49
Divestitures
-----4.88-
Investment in Securities
46.426.4-33.46-86.95-384.76-0.96
Other Investing Activities
39.6527.29169.29-39.3511.2532.55
Investing Cash Flow
18.55-139.28-211.55-344.65-540.4-197.82

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-----5.5
Total Debt Issued
-----5.5
Short-Term Debt Repaid
------14.5
Long-Term Debt Repaid
------0.4
Total Debt Repaid
------14.9
Net Debt Issued (Repaid)
------9.4
Common Dividends Paid
-17.9-17.9-154.1-102.74-102.74-102.93
Other Financing Activities
50----9
Financing Cash Flow
32.1-17.9-154.1-102.74-102.74-103.33

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-00-00.030.1-0.02
Net Cash Flow
422.96100.49-140.1712.84-253.21163.45

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
304.8164.69-121.89241.84226.33227.72
Free Cash Flow Growth
---6.85%-0.61%42.42%
Free Cash Flow Margin
51.52%10.37%-18.46%23.75%21.55%18.75%
Free Cash Flow Per Share
0.300.06-0.120.240.220.22
Levered Free Cash Flow
934.98-36.59-260.4186.77121.34113.97
Unlevered Free Cash Flow
934.98-36.59-260.4186.77121.4114.11

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
34.1226.639.1488.1691.5585.63
Change in Working Capital
778.49778.49-12.18112.45113.75129.06